Spark Biopharma is Drug Discovery in South Korea that focus on protein identification technology business. Founded in 2016. They cover business area such as developer, therapeutic drug, small-molecule therapeutic, biology, domestic original technology, new drug candidate, image-base screening technology, fluorescent skeleton probe, therapeutic candidate, cardiovascular and other metabolic disease.
2016
( 8 years old in 2024 )
Protein Identification Technology
-
Gwanak-ro, Gwanak-gu
7th Floor, 134
Seoul, 08791
South Korea
Private
developertherapeutic drugsmall-molecule therapeuticbiologydomestic original technologynew drug candidateimage-base screening technologyfluorescent skeleton probetherapeutic candidatecardiovascular and other metabolic disease
* We use standard office opening hours in near Spark Biopharma's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Spark Biopharma is Drug Discovery business from South Korea that founded in 2016 (8 years old in 2024), Spark Biopharma business is focusing on Protein Identification Technology.
Spark Biopharma headquarter office and corporate office address is located in Gwanak-ro, Gwanak-gu 7th Floor, 134 Seoul, 08791 South Korea.
Spark Biopharma was founded in South Korea.
In 2024, Spark Biopharma is currently focus on protein identification technology sector.
Above is snippet of Google Trends for "protein identification technology" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Spark Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
